Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas

B-cell non-Hodgkin lymphoma; B-cell receptor; Acalabrutinib

Detalhes bibliográficos
Autores: Carvalho Santos, Juliana, Roue, Gael, Ribeiro, Marcelo, Marin Niebla, Ana, Profitós-Pelejà, Núria
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/8784
Acesso em linha:https://hdl.handle.net/11351/8784
Access Level:acceso abierto
Palavra-chave:Hodgkin, Malaltia de - Tractament
Medicaments antineoplàstics - Ús terapèutic
DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::/uso terapéutico
id ES_d637bc8a26e5b4c76cbd3a72fc366501
oai_identifier_str oai:recercat.cat:11351/8784
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
title Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
spellingShingle Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Carvalho Santos, Juliana
Hodgkin, Malaltia de - Tractament
Medicaments antineoplàstics - Ús terapèutic
DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::/uso terapéutico
title_short Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
title_full Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
title_fullStr Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
title_full_unstemmed Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
title_sort Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
dc.creator.none.fl_str_mv Carvalho Santos, Juliana
Roue, Gael
Ribeiro, Marcelo
Marin Niebla, Ana
Profitós-Pelejà, Núria
author Carvalho Santos, Juliana
author_facet Carvalho Santos, Juliana
Roue, Gael
Ribeiro, Marcelo
Marin Niebla, Ana
Profitós-Pelejà, Núria
author_role author
author2 Roue, Gael
Ribeiro, Marcelo
Marin Niebla, Ana
Profitós-Pelejà, Núria
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Profitós-Pelejà N, Carvalho Santos J, Roué G] Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. [Marín-Niebla A] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ribeiro ML] Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. Laboratory of Immunopharmacology and Molecular Biology, Sao Francisco University Medical School, Braganca Paulista, Brazil
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Hodgkin, Malaltia de - Tractament
Medicaments antineoplàstics - Ús terapèutic
DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::/uso terapéutico
topic Hodgkin, Malaltia de - Tractament
Medicaments antineoplàstics - Ús terapèutic
DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::/uso terapéutico
description B-cell non-Hodgkin lymphoma; B-cell receptor; Acalabrutinib
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8784
url https://hdl.handle.net/11351/8784
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancers;14(4)
https://doi.org/10.3390/cancers14040860
info:eu-repo/grantAgreement/ES/PE2017-2020/CD19%2F00228
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420817666801664
spelling Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell LymphomasCarvalho Santos, JulianaRoue, GaelRibeiro, MarceloMarin Niebla, AnaProfitós-Pelejà, NúriaHodgkin, Malaltia de - TractamentMedicaments antineoplàstics - Ús terapèuticDISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-HodgkinOther subheadings::Other subheadings::Other subheadings::/drug therapyCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic AgentsOther subheadings::Other subheadings::/therapeutic useENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no HodgkinOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicosOtros calificadores::Otros calificadores::/uso terapéuticoB-cell non-Hodgkin lymphoma; B-cell receptor; AcalabrutinibLinfoma no Hodgkin de células B; Receptor de células B; AcalabrutinibLimfoma no Hodgkin de cèl·lules B; Receptor de cèl·lules B; AcalabrutinibThe proliferation and survival signals emanating from the B-cell receptor (BCR) constitute a crucial aspect of mature lymphocyte’s life. Dysregulated BCR signaling is considered a potent contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B-NHLs). In the last decade, the emergence of BCR-associated kinases as rational therapeutic targets has led to the development and approval of several small molecule inhibitors targeting either Bruton’s tyrosine kinase (BTK), spleen tyrosine kinase (SYK), or phosphatidylinositol 3 kinase (PI3K), offering alternative treatment options to standard chemoimmunotherapy, and making some of these drugs valuable assets in the anti-lymphoma armamentarium. Despite their initial effectiveness, these precision medicine strategies are limited by primary resistance in aggressive B-cell lymphoma such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), especially in the case of first generation BTK inhibitors. In these patients, BCR-targeting drugs often fail to produce durable responses, and nearly all cases eventually progress with a dismal outcome, due to secondary resistance. This review will discuss our current understanding of the role of antigen-dependent and antigen-independent BCR signaling in DLBCL and MCL and will cover both approved inhibitors and investigational molecules being evaluated in early preclinical studies. We will discuss how the mechanisms of action of these molecules, and their off/on-target effects can influence their effectiveness and lead to toxicity, and how our actual knowledge supports the development of more specific inhibitors and new, rationally based, combination therapies, for the management of MCL and DLBCL patients.G.R. acknowledges supports from Fondo de Investigación Sanitaria PI18/01383, Spanish Ministry of Science and Innovation, European Regional Development Fund (ERDF) “Una manera de hacer Europa”. J.C.S. holds a Sara Borrell research contract from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (CD19/00228).MDPIInstitut Català de la Salut[Profitós-Pelejà N, Carvalho Santos J, Roué G] Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. [Marín-Niebla A] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ribeiro ML] Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. Laboratory of Immunopharmacology and Molecular Biology, Sao Francisco University Medical School, Braganca Paulista, BrazilVall d'Hebron Barcelona Hospital Campus202320232022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8784Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCancers;14(4)https://doi.org/10.3390/cancers14040860info:eu-repo/grantAgreement/ES/PE2017-2020/CD19%2F00228Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/87842026-05-29T05:05:01Z
score 15.812455

Registos relacionados